Integrin Signaling at 2hr and 48hr Post-Eccentric Exercise in Heat Treated Rat Skeletal Muscle by Graham, Zachary Aaron
Integrin signaling at 2hr and 48hr post- 
eccentric exercise in heat treated rat skeletal 
muscle 
Zachary Aaron Graham 
 
Committee Members 
Phil Gallagher, PhD (Advisor) 
Chad Touchberry, PhD 
Phill Vardiman, PhD  
 2 
Table of Contents …………………………………………………………………..2    
List of Abbreviations……………………………………………………………….6 
Abstract ...…………………………………………………………………………..7 
Chapter 1: General Introduction………………………………………………….9 
 Integrin Signaling ……………………………………………………….......9 
 Theoretical Basis …………………………………………………...……….10 
 Statement of the Problem ………………………………………...…………10 
 Hypothesis and Specific Aims ……………………………………...………11 
 Rationale ………………………………………………..…………………..11 
Chapter 2:  Review of Literature ……………..………………………………….13 
 Introduction ………...……………………………………………………….14  
  Mechanotransduction …...………………………………...………...14 
 Integrin Alpha7Beta1 …………………………………………………….....15 
  Regulation with Damage ……………………………………………15 
 FAK …………………………………………………………………………17 
  FAK with Integrins ………………………………………………….17 
  FAK Phosphorylation ……………………………………………….18 
  FAK and Shear Stress ……………………………………………….18 
  FAK and Cardiac Hypertrophy …………………………...………...21 
 c-Src …………………………………………………………………………23 
  SH4 ………………………………………………………………….23 
  SH3 ………………………………………………………………….24 
   Figure 2.1……………………………………………………26 
  SH2 ………………………………………………………………….27 
  SH1 (The Kinase Domain) ………………………………………….28 
  The C-Terminal Tail and the Role of Csk …………………………..30 
 PI3K/Akt/mTOR Pathway ………………………………………………….32 
 3 
  PI3K ………………………………………………………...………32 
  Akt …………………………………………………………………..33  
  mTor ………………………………………………………………...35 
  ERK1/2 ...............................................................................................37 
  ERK1/2 and MEK ……………………………………………....…...37 
  ERK1/2 Activation …………………………………………………..38 
 Heat shock protein 25/27 and 70/72…………………………………………39 
  Hsp and Integrin Signaling ………………………………………….39 
  Hsp, FAK and Anti-apoptosis………………………………………..40 
  Hsp and Eccentric Exercise……………………………………….....40 
 Conclusion …………………………………………………………………..41 
  Figure 2.2…………………………………………………………….42 
Chapter 3:  Methods ……………………………………………………………….43 
 Animals Used  ……………………………………………………………….43 
 Eccentric Exercise …………………………………………………………..43 
 Heat Shock ………………………………………………………………….43 
 Muscle Samples …………………………………………………………….44 
 SDS-PAGE …………………………………………………………………44 
 Western Immunoblotting …………………………………………………...45 
 Quantification ………………………………………………………………45 
 Statistics …………………………………………………………………….45 
Chapter 4:  Results ………………………………………………………………..47 
 Description of figures……………………………………………………….48 
  Beta 1……………………………………………………………….50 
  Total ERK1/2……………………………………………………….53 
  Phospho ERK1/2……………………………………………………56 
  Ratio of p/t ERK1/2…………………………………………………59 
 4 
  Total c-Src…………………………………………………………..62 
  Phosph c-Src………………………………………………………...65 
  Ratio of p/t c-Src…………………………………………………….68 
Chapter 5:  Discussion …………………………………………………………….69 
 Limitations ………………………………………………………………….76 
 Future Research …………………………………………………………….76 
Works Cited  ………………………………………………………………………77 





















List of Abbreviations 
EE=ccentric exercise 
ERK1/2=Extracellular-signal regulated protein kinase 
FAK=focal adhesion kinase 
HS=heat shock 








VLR=vastus lateralis red 






Introduction:  Integrins (IN) are heterodimers made up of an alpha subunit and a beta 
subunit.  They are transmembrane proteins that are capable of detecting and relaying 
signals from the extracellular matrix to the cytosol and vice versa.  IN have been 
implicated in mechanotransduction and shear stress by becoming activated by these 
forces and starting intracellular cascades.  Heat shock proteins are a highly conserved 
group of proteins that help protect cellular function by chaperoning and refolding proteins 
and by maintain actin structures of the cellular membrane.  Methods:  Heat shocked 
(HS+EE) and non-heat shocked (EE) male Wistar rats performed a two hour downhill 
treadmill exercise.  The soleus (SOL), vastus lateralis white (VLW) and red (VLR) were 
harvested at 2hr and 48hr post exercise and tested for IN beta1 subunit, total and 
deactived c-Src527 and total and active ERK1/2 via SDS-PAGE and Westerm 
immunoblotting.  Results:  There were no significant differences between the treatment 
groups (EE and HS+EE) as well as the treatment groups versus controls in all muscles 
and at both time points.  Conclusion:  A two hour downhill treadmill protocol is not 
sufficient enough to activate IN and downstream proteins in healthy HS+EE and EE rat 
skeletal muscle at 2hr and 48hr post-exercise. 
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The forces faced by skeletal muscle during an eccentric exercise protocol are generally 
too much to maintain cellular integrity.  This can cause significant trauma to the muscle, 
inciting cellular reconfiguration and inflammation.  How the muscle cell protects itself 
during these high stress events is not clearly understood.  One possibility is cellular 
mechanotransduction, the stretching of the cellular membrane, which may activate a 
membrane protein and start a signaling cascade aimed at cell survival.  Integrins are a 
family of proteins located on the membrane that have been shown to sense 
mechanotrandsuction (10) and could be a viable communicator in damaged muscle cells. 
Integrins are necessary proteins that span the length of the cell membrane (39).  They 
have the unique ability to receive signals from outside the cell and relay that information 
to various proteins inside the cell (50).  The role of integrins has mainly been looked at in 
pathological conditions such as cancer (96) and muscular dystrophy (12) as well as cells 
where stress is constant, such as endothelial (105) and cardiac cells (85), but not a lot is 
known within healthy skeletal muscle.  Integrins respond to cytoskeletal stress and shear 
stress by becoming conformationally changing their structure, activating proteins in the 
cytoplasm (15). 
A protein responsible for potential cell survival via integrin signaling is focal adhesion 
kinase (FAK).  FAK is located around focal adhesions, the area where integrins interact 
with the extracellular matrix.  This could allow for quick signaling from integrins when a 
stress may be present.  FAK is also responsible for activating two signaling pathways 
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which serve to maintain cell survival:  the ERK1/2 pathway mediated by c-Src (17) and 
the PI3K pathway (18).   
Another set of proteins that protect the cell are heat shock proteins (Hsp).  These proteins 
respond to cell stress and protect the cell by chaperoning proteins and refolding damaged 
or misfolded ones (36, 110).  It has also been shown that a specific type of Hsp, Hsp27, 
can activate FAK (56), perhaps causing another way to combat the cell during stress.  
These proteins respond quickly in an effort to maintain homeostasis and have been found 
to be upregulated with eccentric exercise (38). 
Theoretical Basis 
The basis behind this study is trying to understand how integrins affect skeletal muscle 
cells during a bout of eccentric exercise in rats.  By examining how integrin signaling 
affects intracellular pathways in cancer and endothelial cells it is possible to extrapolate 
and predict what may happen in heat shocked skeletal muscle and non-heat shocked 
muscle after eccentric exercise.  The forces that get transmitted along the membrane of a 
skeletal muscle cell will be detected through integrins and the cell will accommodate 
those signals for increased chances of cell recovery and survival.  Heat shocking before 
the exercise, should provide even more insurance for cell stability and survival. 
Statement of the Problem 
Currently, there is no study that has looked at integrin signaling in heat shocked skeletal 
muscle prior to a bout of eccentric muscle damage. The purpose of this study is to 
compare integrin recruitment and FAK signaling following exercise induced muscle 
damage in heat-treated versus non heat-treated rats.  
 10 
Hypothesis and Specific Aims 
Hypothesis 
The hypothesis of the study is that eccentrically exercised rats will have an increase in 
integrin signaling versus controls and the heat shocked proteins will augment intracellular 
protein levels responsible for cell survival. 
Specific Aim #1 
Determine if heat shocked and control rats that have been eccentrically exercised have 
changes in expression of the muscle specific integrin alpha7beta1 via densiometry of total 
beta1 subunit; total, phosphorylated and the ratio of phospho to total ERK1/2; and total, 
phosphorylated and the ratio of phospo to total c-Src in the soleus (S), vastus lateralis red 
(VLR) and vastus lateralis white (VLW).  Phosphorylated c-Src will be looked at tyr site 
527 and a decrease in content will be a sign of activity in the cell. 
Rationale 
The rationale for doing this study is to increase the body of literature regarding the role of 
integrins and skeletal muscle.  Integrins have been studied heavily in pathological 
conditions but not as much in response to exercise in muscle.  For example, in 
Duchenne’s muscular dystrophy, integrin levels are staggeringly high as the cells try to 
maintain their ability to sustain themselves after the force of a contraction.  Trying to 
treat muscular dystrophy with Hsp has been hypothesized because of the role the protein 
takes in the cell.  This makes sense in that Hsp have thought to be a way help muscle 
recover cell function in dystrophin lacking cells and other myopathies.  In healthy 
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skeletal muscle, if integrin levels increase during exercise it may provide another 
mechanism to protect the cell and return to homeostasis quicker. 
In cancer cells, mediating proteins through integrins is considered harmful, as it keeps the 
cells alive and growing.  However, in skeletal muscle this is beneficial.  The downstream 
proteins have been studied extensively and will show further proof of the role of integrins 















Review of Literature 
Introduction 
Integrins (IN) are a family of transmembrane proteins that help stabilize the cell while 
also taking cues from the extracellular matrix to communicate with the interior of the 
cell.   This activates varying cascades and intracellular pathways (70).  In mammals, IN 
are composed of 8 beta subunits and 18 alpha subunits that can come together to form a 
set number of 24 integrins (39).  These combined subunits are then capable of detecting 
extracellular activity to direct intracellular communication and vice versa (39).  They are 
also responsible for cell-to-cell interactions during muscle maturation and in diseases 
related to skeletal muscle, such as muscular dystrophies (67).   
While the number of publications in the literature concerning IN and mammals is 
extraordinary (typing ‘integrins mammals’ in PubMed listed 35,822 hits as of this 
writing), this review will concern itself with the diversity of actions in regards to proteins 
downstream of IN signaling and the diversity of actions that aspects of a particular 
protein can have (c-Src, in particular).  All of this will be used to help extrapolate on how 
fluid or shear stress (SS) and mechanotransduction (MT), which are constant forces for 
cells like vascular endothelial cells, could possibly relate to eccentric exercise (EE) and 
how this may alter certain activities of intracellular proteins in skeletal muscle (SM).  It 
needs be noted, however, no studies can be located regarding alterations of IN signaling 
by SS in SM.  There have been few studies published regarding IN and MT and 
alterations to their downstream changes concerning mature SM cells.  However, there are 
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a litany of studies regarding changes to SS and MT with IN signaling in endothelial 
vascular cells, cancer cells, osteoblasts, cardiac myocytes and so on.  With that being 
stated, there must be an underlying assumption that similar mechanisms could happen in 
regards to mature SM, especially considering these functions in cardiac cells.  It is 
understood that it may not be the case but it is necessary for the context of this paper.   
Furthermore, this review will highlight how IN pathways may affect four distinct proteins 
related to SM signaling and function: focal adhesion kinase (FAK), c-Src, 
phosphoinositide 3-kinase (PI3K) and its downstream proteins, along with the mitogen 
activated protein kinase (MAPK) extracellular signal-regulated kinase 1/2 (ERK1/2).  
After the independent roles and characteristics of these proteins have been briefly 
described there will be a section that deals with relationships each may have with the 
other and brief extrapolations regarding eccentric exercise.  The last section of the paper 
will be dedicated to a brief discussion of heat shock proteins (HSPs) and how specific 
ones, Hsp25/27 and Hsp70/72, react to EE. 
MECHANOTRANSDUCTION  
MT is the ability of the cell to detect a physical act upon the cytoskeletal membrane and 
transmit it into an intracellular signal.  These forces can be detected from stretching  
(similar to muscle contractions) or SS (blood flowing through vascular endothelial cells, 
for example) in a large variety of cells.  In SM, p70S6K is a protein upregulated during 
exercise that ultimately increases protein synthesis, cellular hypertrophy and cell survival.  
Baar and Esser used electrical stimulation to cause high-resistance muscle contractions in 
the plantarflexors to cause an eccentric load to the dorsiflexors (tibialis anterior (TA) and 
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extensor digitorum longus (EDL)) (3).  Twice a week the muscles were contracted at a 
rate of 60 times per 20 minutes, with the protocol lasting 2 months.  In TA they saw a 
14.3% increase in muscle size with an increase of 13.9% in EDL.  They also saw a 
positive correlation with muscle mass and change in p70S6K (r=.998), demonstrating that 
stretch-based MT mediated by electically-stimulated contraction increased protein 
synthesis in rat SM.  In conditions such as Duchenne’s muscular dystrophy, MT is 
hindered in the muscle cell because dystrophin is not there to dissipate the force through 
the cell membrane.  In a Duchenne’s muscular dystrophy mouse analog with increased 
Akt expression, another protein responsible for cell growth and survival, there was an 
increase in eccentric force prevention and a vast increase of genes related to z-disks and 
constameres (8).  Contractions were made in vivo by using an electronic stimulator to 
produce eccentric forces over a course of three weeks.  After this training set, there was 
only a 14.8% drop in force resistance over a set of eccentric contractions compared to 
controls, which lost 34.8%.  This shows that repeated bouts of MT in SM can alter the 
biochemical processes inside the cell, increasing protein content and cell size, all in a 
manner to protect the cell.   
INTEGRIN ALPHA7BETA1 
Regulation with Damage 
There have been limited studies regarding IN signaling in mature SM.  The principal IN 
in SM is alpha7beta1.  The alpha subunit determines the outside signal through different 
ligand detections and the beta subunit is connected to actin via different protein 
complexes (10).  IN connect myofibers to the ECM and they are heavily located around 
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myotendenous junctions (MTJ) (44).  In a study to find the necessity of each subunit, 
researchers noted a decrease in the alpha7 IN gene, ITGA7, in patients with noted 
congenital myopathy.  By using three case studies and RT-PCR, they were able to show 
that these decreases are caused by two different base pair mutations in the intron for two 
of them and a substitution of another base pair that caused a premature stop codon in the 
other case study (34).  This indicates that coding for alpha7 in necessary for normal 
muscle functions.  It also appears that this IN aids in muscle recovery.  Sprague-Dawley 
rats that had their soleus transversely cut to create damage followed by suturing the 
fascia, allowing the injured muscle to heal.  The alpha subunit was upregulated at days 3, 
10 and 28 afterwhich they returned to basal levels.  The beta subunit was present in all 
time courses but ablated during days 3 and 10 (44).  This shows that during healing and 
regenerations, alpha7 plays a large role in formation and recovery but at rest, beta1 is 
responsible for the function of the complex.  Using wild type (WT) and alpha7 null mice 
and exposing them to a downhill treadmill protocol, the researchers were able to 
determing if there was any integrin input to help with recovery.  There was a 5.4 fold 
increase in alpha7 mRNA in WT versus animals that did not exercise 3 hours after, with a 
return to baseline at 24 hours.  There was also an increase in alpha7 concentration at the 
MTJ immediately post exercise and 24 hours later (11).  Furthermore, a study comparing 
used WT and mice with varying increased alpha7BX2 isoforms (the most common in 
adult SM) that were exposed to a downhill treadmill protocol.  It was found that there 
was an increase in MAPK activity, specifically c-JNK, p38, and ERK1/2 in WT.  
However, in the mice overexpressing the alpha7BX2 isoform, there was no change from 
pre to post exercise, meaning that IN signaling could be a negative regulator of MAPK.  
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This study also showed that the overexpressing mice attenuated all signals through the 
PI3K pathway, especially p70S6K (10), indicating that IN may inhibit cell growth and 
cell survival by shutting off the PI3K pathway. 
FAK 
FAK and Integrins 
Focal adheision kinase (FAK) is a 125 kDa non-receptor tyrosine kinase that is located in 
the cytoplasm (46).  X-ray chrystallography has shown that FAK contains four main 
regions:  an N-terminal FERM (band 4.1, ezrin, radixin, moesin homology), a linker 
region that contains the main phosphorylation site, an active kinase site and a focal 
adhesion targeting (FAT) site (59).  There had been some controversy regarding the size 
of FAK.  Guan and Shalloway (30) later found that the 120 kDa protein was identical to 
the 125 kDa protein.  By using NIH3T3 cells and putting them on various plates with or 
without fibronectin (a ligand for beta1 integrins) they showed that the 120 kDa protein 
and the 125 kDa move at the same rate, translocated similarly and also bound similarly to 
c-Src.  They suggested that the differences may be due to different regulators, i.e. 125 
kDa is regulated by IN and 120 kDa is regulated by intracellular mechanisms. But 
another important outcome from this study is that it showed that IN activation, by the 
changes that occurred with the cells along with the presence of fibronectin, caused 
phosphorylation of FAK as seen by Western blotting.  FAK has also been shown to be 
directly linked to beta1 and beta3 subunits of IN in an in vitro assay (90).  By using 
chicken embryonic cells (CE) and genetically cloning the binding templates of multiple 
beta integrin subunits, Schaller and colleagues were able to show that FAK specifically 
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targeted the beta1 cloned peptide template.  This is especially important considering the 
beta1 are in SM.   
In a paper by Tzima (105), it was demonstrated that IN could be activated by SS, 
increasing both ligand affinity and binding to the extracellular matrix (ECM) in 
alpha5beta3 IN.  Tzima perfused bovine aortic endothelial cells (BAEC) with a buffer 
and kept the cells either static or exposed them to SS that is consistent with physiological 
levels for arteries.  This type of IN activation may be especially important when 
considering EE and the stress put on the muscles by the hypermaximal load. IN clustering 
has also been shown to activate tyrosine kinase proteins, which can activate FAK (50).  
In this study, the authors used a human epidermal carcinoma line of cells (KB cells) that 
had been incubated in a solution containing specific antibodies that, when looked at by 
fluorescent microscopy, induced IN clustering.  After running these samples with SDS-
PAGE, it showed that those cells which were clustered had a higher than basal level of 
FAK activation.   
FAK Phosphorylation 
It has been shown that FAK’s main activation site is carried out at tyrosine (tyr) 397 and 
that this site is activated by autophosphorylation (89).  Schaller was able to find this out 
by creating an amino acid genetic map and creating mutants at the various spots they 
believed the autophosphorylation took place.  This autophosphorylation seems to be 
integral in the binding of c-Src to form the FAK/Src complex (19).  By using CE, Cobb 
was able to genetically alter and control transcription and expression by transfection with 
a virus to encode FAK or c-Src.  After lysing, they were able to do protein analysis by 
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SDS-PAGE.  The results showed that FAK and c-Src, specifically the SH-2 homology, 
were binded well.  X-ray chrystallography showed that two of the four main sections of 
FAK, the N-terminus FERM sections and the kinase domain, are the ones responsible for 
autoinhibition (59).  In the autoinhibition mode, the various lobes of the FERM subunit 
bind with the kinase domain, effectively blocking tyr 397, which lies in between the two.  
The authors explain that the mechanism for autophosphorylation is still unknown 
although they state that it appears that a slight shift in FERM, possibly caused by IN 
signaling, is all that is required for the activation of the tyr 397.  
There is also another major site that are responsible for full kinase activity of FAK and 
they are often placed together and mentioned as tyr 576/577.  Calalb, et al., showed that 
this site is activated by c-Src.  Using BALB/3T3 fibroblasts and creating a tryptic 
phosphopeptide map with labeled FAK, they were able to determine the activated sites by 
showing broken down FAK complexes.  They then used DNA plasmids and infected 
COS-7 cells.   By running the potential sites with an array of electric tests and affinity 
and structural tests, they concluded that this previously undetermined site was tyr 
576/577 (14).  By using FAK-null cells that were transfected to create various types of 
FAK Owen and colleagues (79) were able to show that tyr 576/577 were need for full 
activation of FAK.  When there was a mutation on the tyr 397, there was no activation 
and cell motility and spreading decreased.  With a functional tyr 397 and mutated tyr 
576/577, motility and spreading were also decreased, although not to the same degree. 
This shows that activation of tyr 576/577 is necessary for full function of FAK.  It 
appears this activation has to happen after tyr 397 activation.  The FERM region 
effectively blocks the activation loop that contains tyr  576/577.  Once tyr 397 becomes 
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activated it destabilizes the kinase domain enough that the activation loop can be 
phosphorylated (59).  The role of FERM can be seen with another experiment.  In a study 
using HEK 293 cells and FAK null cells that were infected to generate a tagged FAK, 
they truncated the FERM region of the protein and saw that there was in increase in 
overall activation of tyr 397.  Even more, the mutated FAK was still able to transduce IN 
related signals via a replication in which the cells were suspended over 30 minutes and 
then placed on a plate of fibronectin (42).       
FAK and Shear Stress 
Helmlinger, et al., have shown that both pulsatile and constant SS can increase calcium 
levels in a cell (35).  In this study, the authors placed bovine aortic endothelial cells (BA) 
in a solution along with a small capillary tube that made them able to control flow 
strength and frequency.  The results indicated that constant and oscillating forces can 
increase calcium concentrations in the cell.  To further this hypothesis, it appears 
different cells have an intrinsic optimal frequency in which outside pressures do not 
matter as long as this pulsatile frequency is met (4).  By using a simple set up that the 
authors called a perfusion bioreactor, they were able to set up a solution resorvoir that 
was then pumped out and through a set of eight channels, flushing solution into contact 
with the cells, and then returned back to the resorvoir.  By doing this, they were able to 
control how fast the pump sent fluid out and at what frequency, ultimately controlling the 
shear force.  These cells multiplied efficiently at a rate very similar to rat lung epithelial 
cells and both of these differed quite a bit from rat small intestine epithelial cells. This 
activation may have significant outcome.  It shows that there are intraspecies difference, 
meaning that different cells in the body react differently to SS.  For example, in 
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endothelial vascular cells there is a constant physiological SS upon them at all times.  
This SS has been shown to activate FAK in these cells (58).  Li and colleagues also used 
aortic endothelial cells with a steady flow across the cells.  There was a marked increase 
in phosphorylated FAK after one minute that gradually faded over the course of an hour.  
This has also been demonstrated with colon cancer cells.  Thamilselvan, et al., (96) have 
shown that FAK is autophosphorylated in colon cancer cells that were exposed to 
increased pressures.  By controlling ambient air pressure in an airtight container, they 
showed that increasing the pressure induced FAK activation.  They also showed that 
increasing the calcium concentration in the cells increased FAK activation.  For further 
diversification of FAK, it has been shown that SS resulting in osteoblast MT causes the 
de-activation of FAK related proteins (112).  Osteoblast-like cells were hit with fluid 
pressure to mimic MT.  With varying percentages of functional FAK, certain downstream 
proteins were severely ablated, showing that FAK is necessary in communicating during 
MT.  Again, this is very important when considering the type of stress that SM deals with 
during eccentric loading.  
FAK and Cardiac Hypertrophy 
The beta1 IN subunit plays a significant role in cardiac hyptertrophy.  By using neonatal 
rat ventricular myocyte (NRVM) cell cultures with increased cell volume caused by 
phenylephrine, Ross, et al., (85) found a genetic increase in beta1 subunits caused an 
increase in cell hypertrophy when using atrial natriuretic factor (ANF), a sign of 
hypertrophy, as a marker.  This shows that the increase in beta1 subunits can control 
intracellular hypertrophy signals.  To further elucidate the role of FAK in hypertrophy 
Torsoni, et al., (101) looked at possible genetic effects that FAK would have in a 
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hypertrophic model.  They used NRVM cell cultures and exposed them to a device that 
stretched them to 115% of their basal length at a frequency of 1 Hz.  They found a 
gradual increase in activated FAK activity over time.  By mutating tyr397, stretch-
induced activity was attenuated.  The study also showed that the mutated FAK had a 
marked decrease in ANF-promoter activity, meaning the FAK could be responsible for 
hypertrophic gene expression via its signaling cascade.  Continuing with hypertrophic 
models, a study by Franchini, et al., (25) found that FAK becomes elevated after 
increasing aortic pressure in rat hearts.  Using Wistar rats, they increase blood pressure 
by putting on an aortic clamp for 60 minutes at 60 mmHg or in a graded fashion that 
increased blood pressure every 10 minutes.  In the graded test they saw a rapid increase if 
FAK phosphorylation.  For the constant clamp, FAK remained constant.  A different 
study by Torsoni, et al., (102) found that stretching myocytes increases FAK activity 
similarly to the previous study.  Using NRVM, they found that by stretching the cells at 
the same protocol used above gave similar results.  However, they also showed that FAK 
may have a precursor that is different than simply IN signaling.  By inhibiting the 
RhoA/ROCK pathway, stretched-induced FAK activation fell significantly.  A correctly 
functioning RhoA/ROCK pathway maintains a stable actin organization so this means 
that if there is an no stable actin on the cell membrane, FAK activity will falter.  Finally, 
in a study by Marin, et al., (64) it was shown that inhibiting Shp2 in NRVM, which the 
authors claim can dephosphorylate activated FAK and lead to apoptosis, increases FAK 
activity.  In stretched cells, Shp2 was significantly decreased as FAK activation 
increased, implying that Shp2 can moderate FAK activity.  They also showed that 
inputing a silenced Shp2 RNA in non-stretched cells leads to higher levels of FAK 
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activation.  Furthermore, when FAK/c-Src complex was formed, there were higher levels 
of the hypertrophic proteins Akt and p70s6k. 
c-Src 
c-Src (pronounced “Sarc”) is a 60 kDa protein and, similarly to FAK, is a non-receptor 
tyrosine kinase that is located within the cytosol (84).  This protein should not be 
confused with v-Src, a viral protein originally found in chicken tumors in 1911 (84).  c-
Src is a member of a larger family of highly conserved protein kinases called Src-family 
kinases (SFK), of which there are 11 in humans (62).  c-Src can be broken down into six 
domains which all have different actions when activated in the cell: Src homology (SH) 4 
which starts at the N-terminal, SH3, unique domain, SH2, the kinase domain (also known 
as SH1), and the C-Terminus.  All members of the SFK have SH4, SH3, SH2 and SH1 in 
common but their exact amino acid structure differs slightly allowing for the different 
characteristics of the family (81).  c-Src SH3 and SH2 are necessary for binding with 
FAK and downstream substrates activation is dependent upon this complex forming (97).  
This happens once the autophosphorylation of the active binding site of FAK, tyr 397, 
becomes open, which then opens tyr 576 and 577, both of which are mediated by Src 
(14).  Two tyrosines at 576 and 577 were replaced with phenylalanines and the level of 
FAK activation was measured.  This switch in amino acids caused a significant decrease 
(about 70% compared to wild type) in FAK activity.  The following are brief descriptions 
of the individual aspects of the main domains of c-Src. 
SH4 
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SH4 is a naturally unfolded domain (also known as intrinsically unstructured or unfolded 
proteins) and this is thought to make it easier to transduce signals by increased flexibility 
and binding ability (27).  SH4 is mainly responsible for most SFK’s membrane 
attachment by transforming the chemical binding sites on the fatty acid part of the cell 
membrane (103).  The actual mechanism behind this is the covalent binding of a 
myristate (a 14-carbon fatty acid) to the N-terminal and the binding/esterification of a 
palmitate (a 16-carbon fatty acid) to the cysteine residues on SH4 [for in depth review see 
(93)].  However, c-Src is a non-palmitating SFK that rapidly moves from the plasma 
membrane to the intracellular organelles, which differs from many of the other SFK’s and 
may explain differences in SFK signaling (47).  SH4 is not only responsible for 
anchoring the cell.  It may also be responsible for plasma membrane blebbing (cellular 
swelling caused by disorganization of actin) by controlling downstream proteins in a c-
Src-dependent manner (32).  The importance of this is that blebbing of the cell may be a 
sign of apoptotic or necrotic events (6).  Blebbing has also been shown recently to be a 
sign of increased cytokine release, mainly interleukin (IL) 6 and tumor necrotic factor-
alpha (TNFa), when compared to apoptotic cells that were not blebbing, and to activate 
T-cells (26).  c-Src has been shown to be necessary for increased cell motility, a possible 
mechanism for mestasis of cancer cells (104).   
SH3 
SH3 is a small domain of 60-80 residues that is made up of three loops in SFK and binds 
to proline rich areas of other proteins (16).  SH3 can have a prominent role in the 
progression of cancer.  Binding of endothelial-derived gene 1 (EG-1) has been evidenced 
to happen fairly easily on the SH3 domain of Src (61).  In this study, Lu and colleagues 
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used human embryonic kidney (HEK) 293 cells to see the interaction of SH3 and 
potential binding abilities with c-Src.  They found that 21 proteins had a 2.5 fold or more 
increase in SH3 binding with EG-1, with c-Src having a 4.8 fold increase.  Furthermore, 
they found that elevated levels of EG-1 correspond with activation of c-Src by decreased 
levels of tyr 419, the active site in human cells.  Elevated levels of EG-1 have been 
witnessed in breast, prostate and colon cancer cells when compared to benign cells (113).  
SH3 binding to ADAM12-L, a metalloprotease shown to have a role in tumor 
progression, has also been attributed to activating c-Src.  This may start signaling 
cascades that deal with mechanically altering the cytoskeleton, proliferation, protein 
migration or keeping the activation of c-Src for a longer duration (94).  If this binding 
does occur and causes prolonged activation of c-Src, then it’s possible that c-Src may 
have a larger impact on cell status than normal and possibly inducing cytoprotection.  
SH3 may also be responsible in binding c-Src to calcium channels, as a deletion of SH3 
decreased c-Src binding to calcium channels in human smooth muscle, which decreases 
calcium channel activity, possibly causing pathologies such as inflammation of the colon, 
which has attenuated calcium channel function (45).  However, the authors stated that 
SH2 is probably able to alter calcium channel function without SH3 binding.  Higher 
cellular levels of calcium has been shown to increase c-Src and is also regulated by SH3 
(68).  This may have an effect of regulating other pathways, especially if considering SM.   
SH3 binding may also play a role in decreasing contraction velocities in a dog myocardial 
infarction model (49).  But perhaps the most important role SH3 does is help in covering 
the main activation site of c-Src and, along with SH2, control the activity of the protein in 
a manner accepted as the switch, the clamp and the latch (33).  c-Src has four main 
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sections involved with this inhibition: SH2, SH3, two kinase lobes that make up the 
kinase domain, a N-terminus lobe and a C-terminus lobe, to which the terminal tail 
containing tyr 527 is attached (84).  The latch part indicates that the inhibitory and 
phosphorylated tyr527 on the C-terminus of c-Src is directly binded with SH2, fully 
attaching SH2 with the C-kinase lobe and forcing SH3 into contact with the N-kinase 
lobe.  All of this together creates the clamp over the activation site.  The switch is merely 
the dephosphorylation of tyr527, opening the activation site to the cytosol (See Figure 
2.1). 
 
Figure 2.1:  Activation of c-Src.  A) A phosphate group on tyr 527 “latches” to 
Src Homology (SH) 2, causing the “clamp” and keeping the active site buried within the 
protein and rendering c-Src inhibited. B) Activation of c-Src is caused by a “switch” in 
phophorylation of tyr 527.  Once the phosphate group is released, the protein linearizes 
and opens tyr 416 to the cystosol where it is quickly phosphorylated and becomes active.  






SH2 is a domain that contains approximately 100 amino acids.  As previously stated in 
the above section, SH2 is quite active in the self-inhibition of the whole protein.  
However, SH2 has many roles outside of inhibiting the phosphorylation of c-Src.  In 
another very important aspect, SH2 is shown to be the main player in binding to FAK.  
Cobb, et al., (19) showed that in chicken embryonic cells (CE) that had specific genetic 
deletions, SH2 was the main binding domain.  By replacing normal SH3 sequences with 
differing variations but each having its own respective normal SH2 sequences, there was 
still stable binding to FAK.  But when they reversed the homolog variants so that SH2 
was altered and SH3 was normal, there was no binding to FAK.  Another role of SH2 is 
the phosphorylation of the p110 subunit of PI3K requires the SH2 domain of c-Src (43).  
Although the authors are fairly confident that it is c-Src, they do give a little leeway by 
stating that it could be any of the SFK.  In this study a prostate cancer cell line that was 
PTEN deficient (PTEN is a regulator of PI3K).  After confirming that other proteins had 
not phosphorylated PI3K in the cells, a c-Src inhibitor was inserted into the cells and the 
authors saw the dissolution of the subunit p85 from p110 while also seeing a marked 
decline in the p110-beta.  Interstestingly, there was not a substantial decrease in Akt 
phosphorylation, meaning that the activation of p110 by SH2 is not required for signal 
propagation downstream of PI3K.  The last act of SH2 that will be covered is its role in 
cell motility, and its ability localize to focal adhesion on the plasma membrane and 
activate FAK (111).  In this multiple experiment study they demonstrated that by 
genetically altering an arganine on position 175 there was a decrease in localization of 
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shortened SH2s to focal adhesions, decreasing binding of the homolog to FAK.  They 
compared this with an abbreviated c-Src that had a fully functional SH2 region but no 
kinase domain and there was full binding to FAK.  They then used a full c-Src but with 
the defect still in the SH2 and the showed that there was little binding and little cell 
motility, implying that SH2 is necessary not only for binding, but for guiding the protein 
to the focal adhesion. 
SH1 (The Kinase Domain),  
The kinase domain (SH1) contains the main activation site for c-Src, tyr 416.  c-Src 416 
is the chicken numbering and it is the literature standard because it was found in chickens 
first (so is tyr 527, the main inhibitory site) even when using human cells (84).  For 
example, when using even human samples, which have the main activations and 
inhibitory sites on tyr 419 and tyr 530, respectively, they are referred to as tyr 416 and tyr 
527.  As previously mentioned, when tyr 527 becomes dephosphorylated , it allows tyr 
416 to open to the cytosol and become ready for activation.   
It has been shown that c-Src can be autophosphorylated.  The first study to show this was 
done by purifying c-Src by immunoaffinity from European field vole 100,000 fold.  
Labeled ATP was then added to the precipitate and the phosphorylation rate was 
measured via SDS-PAGE (83).  In 1995, Osusky showed by an autokinase assay that site 
416 of a wild type c-Src has an autophosphorylation affinity approximately 10x (in a 
solution with 26 mM Mg/ATP) than that of site 527 on a mutated c-Src with an amino 
acid change on tyr 416, demonstating the protein prefers to be activated (78).  But it also 
shows that by being able to control its own inhibition site, c-Src can actually down 
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regulate itself if the concentration of ATP is high enough.  When the concentration of 
Mg/ATP was increased, phosphorylation of tyr 527 increased, inactivating the protein.  
Another interesting finding from this study is directed to whether autophosphorylation 
happens via intra or inter molecular activity.  By purifying extracts to the point where 
they could not identify other tyrosine kinases they placed in the extract in differing 
dilutions of a phosphate buffer.  They assumed that if it was intramolecular there would 
be constant rates despite increasing concentrations and and if it were intermolecular it 
would be linearly related to the increasing concentration.  What they found was tyr 416 
was shown to be mostly intermolecularly phosphorlyated while tyr 527 in mainly 
intramolecularly activated.   
The activation of tyr 416 can be seen in a study using hepatocyte growth factor (HGF) in 
HuCCA-1.  When exposing these cells to HGF, there was an increase in cell proliferation 
and tumor invasion.  This corresponded to an increase in c-Src/FAK complexes.  
Interestingly, the experiment showed that the c-Src/FAK complex was formed before 
FAK phosphorylation by looking at the time course of activation (82).  However, 
inhibition of c-Src has been shown to decrease mestasis in breast cancer cells.  By 
creating activated or unactivated cancer genes and infecting them into mice to look at the 
effects in vivo, Rucci and partners used a c-Src pharmacological inhibitor to see the 
effects on lethality and tumor size. They saw a 2.5 decrease in mortality in the animals 
that had the inhibitor injected and there was no behavior that would indicate that the 
injection was harmful.  In a mouse strain in which there was a kinase dead dominant gene 
with a mutation to tyr 527 (to ensure very small rates of phosphorylation) there was a 
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decrease in tumor size and mestasis, indicating less cancer activity.  The authors claim 
that this may yield a potential therapy to breast cancer patients (86).  
As with FAK, activated c-Src can play a role in cardiac hypertrophy.  In a study that used 
a treatment of Endothelin-1 (E1) it was shown that EI did not increase total c-Src but it 
did increase phosphorylation of the active site by immunoblotting.  To confirm this they 
used a c-Src autophosphorylation assay and a general c-Src activation assay and found 
that treatment of E1 had a seven-fold increase in c-Src activity.  Using the ANP marker 
for cardiac hypertrophy, the study showed an increase in ANP promoter activity and this 
was decreased 50-60% with c-Src inhibitor Csk (51).  Finally, using cat cardiac myocytes 
that had been exposed to an increase in pressure-load, Kuppuswamy, et al., saw in 
increase of activated c-Src at the cytoskeleton, indicating that cellular membrane and IN 
dynamics may play a role recruiting c-Src for downstream signaling (54).       
The C-terminal Tail and the Role of Csk 
The C-terminal tail (CTT) contains the inhibitory site, tyr 527, which is phosphorylated 
by C-terminal Src kinase (Csk).  As stated before, in the inhibitory state of c-Src, tyr 527 
binds to the SH2 region, effectively locking tyr 416 in the middle of the protein.  Okada 
and Nakagawa (77) were the first to see that a protein kinase phosphorylated tyr 527 in a 
non-truncated protein.  By purifiying non-neuronal and neuronal c-Src from neonatal rat 
brains and breaking them down, they were able to see a protein that co-migrated, along 
with a peptide created to bind to CTT.  This protein that co-migrated they named Csk.   In 
2002, Ogawa and colleagues were able to determine the structure of Csk via 
crystallography.  What it showed was a structure very similar to c-Src.  There was an 
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SH2, SH3, and a very similar kinase domain that also had two lobes.  The main 
difference was the SH2 was located in the top left of the N-terminal kinase domain, 
where c-Src SH2 is located near the C-terminal kinase domain (76).  Later, the Nakagawa 
lab discovered that an unidentified protein negatively regulated c-Src at the tyr527 site 
(71).  They used neonatal rat brain c-Src again and mutated the try527 site to a 
phenylaline.  They saw that there was an increase in c-Src activation in the presence of 
Csk.  To confirm this, they coded the gene and found that the sequence matched well.  
They also saw that there was no autophosphorylation site like most SFK’s and there was 
a stop codon where tyr527 should be.  They mentioned that this could be very important 
to its regulatory and substrate reactions.    Nada, et al., showed in vivo that Csk was a 
negative regulator of c-Src.  Using Csk-deficient mouse embyros, they were able to show 
those embryos that lacked the ability to code Csk had increases in c-Src activation (72).  
By the use of flouresence resonance energy transfer (FRET) it was found that Csk 
binding protein (Cbp) is responsible for an activated Csk being recruited to the cell 
membrane where c-Src is located (66).  Levinson, et al., showed by crystallography of 
activated Csk and c-Src that the active region of Csk binds very close the the C-terminal 
tail and the try527 of c-Src is in a desirable position for easy access to the donor proton 
(57).  These authors also showed, by surface plasmon resonance, that Csk can 
differentiate between active and inactive c-Src.  They placed an actived sequence of the 
CTT c-Src into the kinase domain and saw that there was no increased binding of Csk.  
They concluded that this was so there was no competition between the active and inactive 
tail fighting over Csk.      
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Now that c-Src and FAK have been discussed about in myriad cell types, the focus of the 
paper will now switch to proteins that have been studied extensively in SM:  PI3K and 
the main proteins that are downstream of it, AKT and mTOR.  There will also be a focus 
of ERK 1/2 and certain Hsp’s.   
PI3K/Akt/mTor Pathway 
PI3K 
PI3K is made up of two subunits: a p110 catalyzing subunit and a p85 regulatory subunit.  
Interestingly, in 1991 Escobedo, et al., discovered that p85 has an SH2 subunit.  Using 
BALB/c 3T3 cell lysates, they were able to purify p85.  By exposing their extract to SDS-
PAGE and cutting out the correct bands they were able to clone the DNA.  What they 
found was that the p85 subunit had an SH3 area and two SH2 subunits (24).  Then in 
1992, a mechanism for PI3K p85 activation was discovered.  Hadari, et al., used live liver 
cells that had been injected with hydrogen peroxide and vanadate (inhibitors of certain 
tyrosine kinases that give rise to similar effects of insulin) or insulin.  After 15 minutes 
the rats had their livers removed.  What they saw was the p85 subunit bound to a 
phosphorylated region of IRS-1 in an immunoprecipatate, meaning that p85 of PI3K is 
attracted to proteins with a phosphorylated tyr (31).  Why this is important can be seen 
with a study completed by Chen and colleagues.  They were able to use mutated and WT 
tyr 397 sites on FAK to determine that the SH2 region of p85 of PI3K can bind to the 
main activation loop of FAK and result in activated PI3K.  The authors mutated the 
various tyr phosphorylation site with phenalynines.  They noticed that p85 binding 
disappeared when the mutation was on the tyr 397 site (18).  This is important 
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considering that autophosphorylation of FAK now can direct traffic in a completely 
different manner because PI3K is attracted to these activated tyr.  In a study using 
fibronectin (an IN activator) covered plates and using human thyroid cells, it was possible 
to see that there was an increase in PI3K cells.  When wortmannin, a potent P13K 
inhibitor, was added the cells became apoptotic, demonstrating the IN-based PI3K 
activation is crucial for cell survival (40).  To see how mechanotransduction Sasai, et al., 
(88) demonstrated how mechanotranduction alters PI3K.  13-day old chicken breast 
muscles were stretched at 1/6 Hz to 110% of their length.  These authors saw an increase 
in cell size that they attributed to the PI3K pathway.  When they added wortmannin they 
saw a 30% decrease in size in control muscles and a 25% decrease in size from the 
stretched cells, showing that PI3K is necessary for stretch-induced muscle growth.  In 
another example, Zhou, et al., used aortic stents to demostrate that stretch induces PI3K.  
By placing stents they were able to look at how stretch can affect vascular smooth 
muscle.  They administered wortmannin for two days before the stent were put it and they 
kept administering until the rats were killed.  In the wortmannin-injected rats, there was a 
significant decrease stretch-induced downstream proteins, demonstrating again that PI3K 
is necessary for stretched-induced hypertrophy signaling (114).    
Akt 
In studies in 1996 and 1997, Alessi and colleagues went about working on the sites and 
mechanisms of Akt activation.  In the former study, they used L6 myotubes to determine 
Akt activation sites in the presence of insulin and/or wortmannin.  They saw that with 
insulin, IGF-1 and wortmannin added to wild type or cells with kinase dead or altered 
threonin (thr) 308 and altered serine (ser) 473 sites that significant activation only 
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happened with IGF-1 and insulin in the wild type, showing that you need both sites for 
complete activation and that activation is PI3K dependent.  By mapping these sites after a 
tryptic digestion, they were able to confirm that they were the major activation sites (1).  
Allesi, et al., (2) found that since wortmannin inhibited the signal there might be 
something responsible for activating Akt downstream of PI3K, specifically its product 
PIP3.  They discovered this from using purified rabbit skeletal muscle and single line 
coding for the region of thr 308 and assaying the reactivity with PDK1, the protein they 
discovered activated thr 308 and that activation was enough to activate ser 473.  Toker 
and Newton (100) then found the same by using two versions of pure Akt, one active and 
the other rendered inactive by temperature, and a pure PDK1.  Since it is known that thr 
308 is activated by PDK1 it is possible to see if ser 473 is autophoshorylated.  The results 
showed the ser 473 activation mirrored that of thr 308 confirming that ser 473 is 
autophosphorylated.  Then in 2005 it was shown that the elusive “PDK2” is actually a 
complex that contains mTOR and rictor (mTORC2).  Using HEK 293 and HeLa cells 
with variations of rictor and mTOR, they showed that ser 473 activation was dependent 
on both of them.  It also showed that the presence of PDK1 with mTORC2 had greater 
activity than just PDK1 alone, implying that ser 473 may be activated first (87).   
Sasai (88) and Zhou (114) saw increases in Akt activity.  Gayer, et al. used a Flexcell 
machine to deform human intestinal epithelial cells in a cell culture.  They were flexed at 
a 1/6 Hz frequency at 110% resting length.    Their findings showed that p85 substrate is 
activated and Akt becomes more active over time in strained cells.  They also showed a 
role of c-Src acting as an upstream mediator in strained cells.  With the use of PP2, a c-
Src inhibitor, they saw a return to normal levels of pAkt and activated p85 in strained 
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cells, hinting that Akt and PI3K activation is downstream of a c-Src dependent 
mechinism in strained cells (28).  Upregulation of Akt via beta1 integrin subunits has 
been shown to protect cells from apoptosis.  Tian, et al., used collagen gel contractions as 
a means of showing apoptosis in human lung fibroblasts.  The cells with higher levels of 
collagen showed better structure than those with minimal amounts.  In those cells with 
low levels up collagen, Akt was upregulated by a virus and these cells were tested for 
levels of anoikis, a type of apoptosis, and it was shown that the upregulation of Akt 
protected the cell from self-termination (99).  Furthermore, Katta, et al., demonstrated the 
mechanical stress from EE in Zucker rats increase activation of Akt in lean rats.  By 
attaching an electrode to the sciatic nerve they were able to simulate eccentric loads in 
the rats.  Their results showed that both active site of Akt were activated directly after 
exercise and then three hours later and that muscle contractions can induce Akt activity 
(48). 
mTOR 
mTOR is a large protein that can interact with various other proteins.  There are two 
forms: mTORC1 and mTORC2.  mTORC1 has a rictor module which allows it to 
activate Akt and MTORC2 has a raptor molecule which is activated by Akt.  In a study 
done by Navé, et al, HEK 293 cells were used to monitor the appearance of mTOR in the 
presence of Akt, insulin and wortmannin.  They saw that labeled mTOR increased 
phosphorylation on its ser 2448 site when combined with Akt.  They also saw a decrease 
in concentration of activation mTOR in the presence of wortmannin, indicating it is 
somewhat PI3K dependent and furthermore that ser 2448 activity did not go down in the 
presence of rapamycin, showing that ser 2448 is not that major attack site of rapamycin 
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(73).  In 2007, it was hypothesized that there could be another direct inhibitor of 
mTORC1.  Wang, et al., used HEK 293 cells and immunoprecipitated them and then 
exposed them to protocols that could control the amount of expression they had.  The 
results showed that in mTORC1 there was a distinct band at 40 kD and mass 
spectrometry revealed that it was proline-rich Akt substrate (PRAS40) (106).  They also 
showed that the presence of insulin could disrupt the binding of PRAS40, demonstrating 
it as a negative regulator of mTORC1.  Kovacina, et al., were able to show a few years 
earlier that PRAS40 was actually an Akt substrate by treating it with insulin, rapamycin 
and wortmannin.  There was no effect from rapamycin compared with insulin, showing 
that the target is upstream of mTOR and its activity was shut down with wortmannin, 
showing its downstream of PI3K (52).   
In a recent study, O’Neil and colleagues used an ex vivo EE protocol with rats in which 
the EDL muscle of the rat was mechanically loaded and an in vivo protocol where they 
attached an electrode to the sciatic nerve and contracted electronically.  Using mTORC1 
downstream target p70S6K (p70) as a marker of mTORC1 activity, they observed that 
EE raised activation of p70 even in the presence of wortmannin, indicated that this 
increase is PI3K independent (75).  These results followed similar results from a previous 
study.  In 2003, Bolster, et al., used rats trained to reach up and grap a high bar, 
simulating concentric and eccentric contractions.  They saw an increase in mTORC1 ser 
2448 activation and also p70 after 10 minutes, showing that muscle contractions can 
induce these proteins (9).  SS can also cause mTOR activation.  Using an oscillatory 
mechanism and HUVEC cultured cells, the authors saw in increase in p70 activity.  They 
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also showed that the addition of rapamycin stopped flow-mediated DNA synthesis, 
showing a role of mTOR in a flowing medium (53).     
ERK1/2 
ERK1/2 and MEK 
ERK1/2 is a 42 and 44 kDa protein that is abundant in all cells throughout the body.  Its 
main activation sites were discovered by Payne, et al.,.  By using a labeled Swiss 3T3 cell 
that had been activated by insulin to assure phosphorylation, the researchers were able to 
digest the protein with trypsin, keeping intact the activation sites, and then mapped and 
sequenced it.  They found that phosphorylation occurs at thr 183 and tyr 185 on ERK2 
(80).  But a question lingered after the Payne study.  They believed that something, either 
autoregulation or a protein kinase, was acting on ERK2.  A year later, Crews and Erikson 
(20) found the answer.  They were able to purify a protein kinase that they termed 
MAPK/ERK kinase (MEK) in murine cells.  After purifiying this protein, they saw a 33 
fold increase in ERK2 activity using a labeled protein and SDS-PAGE.  In a study by 
Butch and colleagues, they looked at the activation of ERK1.  They mentioned that the 
activation site for ERK1 is a thr 202 and tyr 204 and the sequence around these is the 
same as in ERK2, suggesting that MEK should show no difference towards either site.  
By mutating the area around the activation site they noticed that basal levels of activation 
decrease drastically with mutations to try 204 and thr 202.  A very interesting result was a 
mutation on the tyr 208 increased phosphorylation by 400 percent but has zero effect on 
activity, an according to the authors this means that the site is necessary for activation of 
thr 202 (13). 
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ERK1/2 Activation 
Dvir, et al., looked at how fluid flow can affect ERK1/2 activity.  By placing rat neonatal 
myocytes in a bioreactor, they were able to push fluid over the cells at 1, 2 or 3 Hz 
frequencies.  They used the presence of angeotensin II as a positive control because it 
activates ERK1/2.  ERK1/2 activation increased dramatically in the pulsed cells 
compared to a static control.  However, differing flows had no effect on the activation 
(22).  Schwachtegen, et al., (91) used HAEC and exposed them to varying flow rates.  
The authors examined egf-1, a gene downstream of ERK 1/2.  With increasing flow 
pressure and time exposed to the flow, they saw an increase in the egf-1 gene promoter, 
demonstrating ERK1/2 activation.  They then exposed the cells to a MEK inhibitor and 
all results were ablated, indicating that ERK1/2 is necessary for this genes expression in 
dynamic cells.  Furthermore, in human lung epithelial cells it has been demonstrated that 
FAK and c-Src may be mediators in ERK1/2 activation.  By placing these cells on 
elastomere membranes and exposing them to a computer driven vacuum, they were able 
to stretch the cells.  What they saw was an increase in proliferation in strained cells 
compared to static cells at each time point.  They also saw an increase in ERK1/2 
activation.  However, when the cells were exposed to PP2, a c-Src inhibitor, they saw a 
decrease in ERK1/2 activity while no decrease in FAK activity, showing that ERK1/2 is a 
downstream player of c-Src in strained cells (17).  The final study that will be covered 
deals with EE and how it plays a role with ERK1/2 activity.  In a study that used rats with 
electrodes attached to their sciatic nerve, researchers looked at four different contraction 
protocols and ERK1/2 activation.  By contracting the muscles to different displacments at 
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a constant frequency, the researchers were able to show that EE generated the most 
ERK1/2 phosphorylation compared to the other protocols (65). 
Hsp 25/27 & 70/72 
Hsp’s are a highly conserved group of proteins that respond to cell stresses such as 
(obviously) increases in cell temperature, incorrectly folded proteins and exercise.  While 
there are many mechanisms and members of the Hsp family, this section will focus on 
Hsp 70/72 (human/rat) and 25/27 (rat/human) and EE.  It is generally accepted that Hsp 
70 and Hsp 25 can disrupt aggregation of proteins and chaperone them away while also 
folding malformed proteins [for reviews see (36) and (110)].  Hsp’s could help in 
stabilizing the cell during EE by refolding membrane proteins (integrins) and/or 
chaperoning them towards the stress. 
Hsp 25/27 and FAK 
While no published studies were found dealing with IN function and Hsp directly in SM, 
it is possible to see an interaction with Hsp and IN signaling via cell culture and cardiac 
tissue.  In NIH3T3 cells overexpressing Hsp27, there was a greater presence of 
phosphorylated FAK and c-Src compared with control cells and an increase in focal 
adhesions.  There was also increased adhesiveness of the Hsp treated cells.  Furthermore, 
when a protein that disrupts actin organization was added, Hsp27 activation of FAK 
disappeared (56).  This insinuates that binding to the cytoskeleton is crucial and further 
implicating IN signaling.  In ischemic rat neonatal ventricular myocytes it was found that 
heat shocked cells increased IN/FAK binding (108).  By immunoprecipitating the β1 
subunit and probing it for FAK activity there was a significant increase in IN/FAK 
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binding at 10 min into ischemia.  It has also been found that heat shocked rats have 
increased FAK activity in left ventricular tissue meaning that FAK may serve as a 
protective mechanism against cell stress (107). 
Hsps, FAK and Anti-apoptosis 
Hsp 70/72 is an anti-apoptotic factor that gets upregulated during cellular stress.  One of 
the ways in which it protects against apoptosis is its ability to protect FAK.  In possum 
renal cells, Hsp 72 was overexpressed by heat treatment or viral transfection and 
incubated with caspase-3, an apoptotic protein that fragments FAK.  In cells that had 
been overexpressing Hsp72 and incubated with caspase-3, those incubated with FAK 
before caspase-3 was added were preserved more and fragmented less than cells that had 
been incubated before FAK was added (63).  It was also shown that Hsp 72 
coimmunoprecipated with FAK, providing evidence that Hsp 72 may preserve FAK by 
physically binding to it and preventing its degradation.  Hsp 27 can also be upregulated in 
an anti-apoptotic manner.  By exposing renal endothelilial cells to a cytotoxin, Hsp 27 
was found to upregulated the fastest of the Hsp family and it was located at sites of high 
focal adhesion turnover (21).   In these cells they also inhibited p38 activation of Hsp 27 
and saw a significant increase in cell death and loss of cellular adhesion.  Cells that were 
overexpression Hsp 27 had increased cellular adhesion and cell death was partially 
ablated when exposed to the cytotoxin.    
Hsp and EE 
Huey used a functional overload model using rats to determine if a constant overload 
(similar to EE) would increase Hsp 25.  By removing the gastrocnemius, she was able to 
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make sure there was a force overload on the plantaris and soleus muscles.  The 
contralateral leg was unaltered to be used as a control.  After 3 or 7 days the muscles 
were removed.  The results showed that were was an upregulation of Hsp 25 expression 
and activity in both muscles compared to the control.  There was also increased activity 
in the 7 day versus day 3 (38).  In 2000, Thompson and workers looked at Hsp 27 and 72 
in biceps brachii following a single bout of EE.  Using a Biodex arm curl machine, the 
non-weight trained subject had to do 2 sets of 25 reps with their non-dominant arm and 
biopsies were taken 48 hrs post.  The study showed a 10 fold increase in the Hsc/Hsp 70 
complex (they mentioned that the antibody used had a larger affinity for Hsp 70 not Hsc) 
and a 2.4 fold increase in Hsp 27 (98).  We can also look at this from a non-
supramaximal test.  Morton, et al., performed a 45 min, non-damaging treadmill test at a 
percentage of the lactate threshold of active but non-trained subjects.  They had vastus 
lateralis biopsies at 1, 2, 3 and 7 days post.  Hsp 72 peaked at day 2 and was significantly 
higher day 7.  There was no change in Hsp 27, suggesting that Hsp 27 may be important 
in helping after muscle damage has occurred and that at submaximal levels, Hsp 70 can 
handle the load (69). 
Conclusion 
Cells face amazing amounts of stress on a daily basis.  The above are examples of 
proteins that may have some amount of activity due to SS or MT via IN signaling.  While 
the first section of the paper dealt with almost every cell but SM, we can try to assume 
that if the protein works in a hypertrophic/prolific manner in a breast cancer cell, there is 
nothing to stop it in a SM cell after a bout of EE.  So, hypothetically, we could say that 
during a bout of EE, MT causes the clustering and activation of INsThis activates and 
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localizes IN, which activates FAK. FAK could then activate the p85 subunit (with two 
SH2) of PI3K, which could cause its own anti-apoptotic and hypertrophic signals 
downstream via Akt and mTORC2.  In another pathway FAK then recruits c-Src SH2 to 
its active site which in turn activates ERK1/2 in a hypertrophic, anti-apoptotic manner.  
FAK could also be protected by a bound Hsp 70/72 to prevent degradation from apoptotic 
proteins.  Hsp27 also activates FAK and goes to focal adhesions to prevent cellular injury 
(See Figure 2.2). 
 
Figure 2.2:  General Integrin Signaling Pathway and Heat Shock Proteins.  
Mechanotranduction and shear stress cause activation of integrins.  This activation causes 
focal adhesion kinase (FAK) to become activated, causing the activation of two separate 
pathways, PI3K and c-Src, both responsible for cell survival.  Heat shock proteins (Hsp) 
have been found in higher levels during membrane stress and exercise.  Hsp 25/27 has 
been found to activate FAK and protect the cytoskeleton and Hsp 70/72 has been found 












The tissue used was taken from an archival source but a general overview will be 
provided.  The study that originally used this tissue source was looking at the PI3K cell 
survival and hyptertrophy pathway and apoptotic MAPK pathway.  The study also used 
hemotoxylin and eoson staining to determine macrophage invasion, nuclei location and 
muscle damage.  Tissue was also used in caspase detection kits as a sign of apoptosis.  
Because of this only IN related signaling will be looked at in the current study. 
Animals Used 
Male Wistar rats were used.  Each weighed between 300-350g before heat treatment.  
They were divided into a control group, an exercise only group (EE) (n=8-9) and heat 
shock group (HS)(n=8-9).  The rats were fasted for 12 hrs pre-heat shock.  All protocols 
were approved by the Animal Care and Use Committee of the University of Kansas 
Medical Center (IACUC #1534) 
Eccentric Exercise 
Rats were randomly put into the EE or HS group.  The exercise consisted of running at 18 
m/min down a grade of -16%.  The rats ran for 5 min with a 2 minute break immediately 
after.  They performed this sequence a total of 18 times, totalling 126 minutes. 
Heat Shock 
Rats were randomized into a control group that internal temperature kepts at 36°C and a 
HS group in which the internal temperature was 41-41.5°C for 20 minutes.  The rats in 
the HS group were anaesthetized and then set in a flotational suit.  The rats were 
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immersed in 42° C water until their body temperature reached the desired internal 
temperature. Saline was injected afterwards to protect agains dehydration.  The HS rats 
performed the exercise bout 48 hours after treatment. 
Muscle Samples 
The soleus, vastus lateralis white and vastus lateralis red were dissected at 2hr and 48hr 
post-exercise.  They were immediately frozen in liquid nitrogen and then stored.  The 
protein was extracted with a cocktail of protein extraction solution (T-Per Tissue Protein 
Extraction; Thermo Scientific, Waltham, MA) phosphotase inhibitor (Halt Phosphotase 
Inhibitor; Thermo Scientific, Waltham, MA), protease inhibitor (Halt Protease Inhibitor; 
Thermo Scientific, Waltham, MA) and PMSF (Nunc; Nalgene International, Rochester, 
NY).  The muscle samples were placed in the solution and ground using a mortar and 
pestle and then centrifuged at 3000rpm for 3 min.   Samples were measured for protein 
content with a BCA protein assay kit (Pierce BCA Protein Assay Kit; Pierce, Rockford, 
IL).  Samples were then put into a ratio to equal 80µg/mL with a corresponding amount 
of HES buffer.  A 5x lane marker was also added to each sample. 
SDS-PAGE 
Electrophoresis will be performed via SDS-PAGE (Mini-PROTEAN 3 cell and PowerPac 
High-Current Power Supply; Bio-rad, Hercules, CA).  Proteins will be ran through a 5% 
stacking gel and varying separating gels (6.0% for beta1 subunit, c-Src and p-c-Src527  
or 10% for ERK1/2 and pERK1/2) at .05 amps.  After the protein marker has started to 
run off the gel the current will be stopped and the gel will be prepared for transfer. 
Western Immunoblotting 
 44 
Proteins will be transfererd onto a PVDF membrane (Amershand Hybond; GE 
Healthcare, Buckinghamshire, England) that has been activated in a 30s immersion in 
methanol.  The proteins will be transferred at .20 amps for 110 minutes and be blocked 
immediately after in a 5% dry milk/TBST solution for an hour.  After blocking, the 
membranes will be placed in a primary antibody (beta1 integrin; Santa Cruz 
Biotechnology, Santa Cruz, CA; c-Src, p-c-Src527, ERK1/2 and p-ERK1/2; Cell 
Signaling, Beverly, MA) diluted with a 1% milk/TBST solution.  Primary antibody 
dulitions will equal 1:500-1:1000 (µL antibody:µL 1% milk solution).  The membrane 
will be incubated overnight in a 4° C refridgerator.  After incubation, membranes will be 
rinsed in 3x5 min washes in TBST and then placed with an anti-rabbit (all proteins are 
anti-rabbit) horsheradish peroxidase linked (HRP) secondary antibody (Anti-rabbit IgG; 
Cell Signaling, Beverly, MA) with a 1:2000 dilution for an hour.  Following incubation 
membranes will be washed with a 2x5 min set with TBST and then 1x5 min with TBS.  
Membranes will be incubated with a HRP chemilumenescent (Amersham ECL Western 
Blotting System; GE Healthcare, Buckinghamshire, England) for 5 minutes and then 
developed with a camera system (Fluorchem SP; Alpha Innotech, San Leandro, CA) 
Quantification 
Densitometry software (AlphaEaseFC V.4.1.0; Alpha Innotech, San Leandro, CA) will be 
used to quantify blot brightness.  Each blot will be measured three times with the average 
number being used. 
Statistics 
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A multivariate analysis of variance (MANOVA) will be used to determine significance. 
If significance is found, then Tukey’s post hoc will be used as a follow up test.  




Male Wistar rats were heat-shocked in a water bath until their internal temperature had 
reached 41.0-41.5°C for 20 minutes.  48 hours later the rats ran for 5 min, followed by 2 
min rest, at 18m/min on a 16° downhill treadmill for a total protocol length of 126 
minutes.  SOL, VLR and VLW muscles were harvested at 2hr and 48hr post-exercise.  
Through SDS-PAGE followed by Western immunoblotting, there was no significant 
difference between total integrin expression measured by the beta1 subunit, total and 
phosphorylated ERK1/2, total and phosphorylated c-Src and the ratio of phosphorylated 
to total ERK1/2 and c-Src in any of the treament groups, CON, EE or HS+EE, in any 
muscle, SOL, VLR or VLW, at any of the time points.  These outcomes demonstrate that 
a downhill, eccentric exercise protocol is not sufficient to alter IN signaling in heat 
shocked or eccentrically exercised rat skeletal muscle versus controls.  
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Descriptions of Figures 
Figure 4.1: Beta1 Subunit in SOL. A) No significant differences between treatments in 
2hr Sol [CON vs EE (p=.980) and HS+EE (p=.966) and EE vs HS+EE (p=.997)]. B) No 
significant differences in 48hr Sol [CON vs EE (p=.947) and HS+EE (p=.998) and EE vs 
HS+EE (p=.938)]. 
Figure 4.2: Beta1 Subunit in VLR.  A) No significant differences between treatments in 
2hr VLR [CON vs EE (p=.962) and HS+EE (p=.868) and EE vs HS+EE (p=.576)].  B) 
No significant differences in 48hr VLR [CON vs EE (p=.407) and HS+EE (p=.576) and 
EE vs HS+EE (p=.915)]. 
 
Figure 4.3: Beta1 Subunit in VLW.  A) No significant differences between treatments 
in 2hr VLW [CON vs EE (p=.877) and HS+EE (p=.709) and EE vs HS+EE (p=.909)].  
B)  No significant difference in 48hr VLW [CON vs EE (p=.304) and HS+EE (p=.289) 
and EE vs HS+EE (p=.999)]. 
 
Figure 4.4: Total ERK1/2 in SOL.  A)  No significant differences between treatments in 
2hr Sol [CON vs EE (p=.935) and HS+EE (p=.999) and EE vs HS+EE (p=.853)].  B)  
No significant differences in 48hr Sol [CON vs EE (p=.342) and HS+EE (p=.447) and 
EE vs HS+EE (p=.959)]. 
    
Figure 4.5: Total ERK1/2 in VLR.  A)  No significant differences between treatments in 
2hr VLR [CON vs EE (p=.978) and HS+EE (p=.855) and EE vs HS+EE (p=.894)].  B) 
No significant differences in 48hr VLR [CON vs EE (p=.913) and HS+EE (p=.389) and 
EE vs HS+EE (p=.427)]. 
 
Figure 4.6: Total ERK1/2 in VLW.  A)  No significant differences between treatments 
in 2hr VLW [CON vs EE (p=.217) and HS+EE (p=.403) and EE vs HS+EE (p=.403)].  
B) No significant differences in 48hr VLW [CON vs EE (p=.645) and HS+EE (p=.713) 
and EE vs HS+EE (p=.427)]. 
 
Figure 4.7:  Phosphorylated ERK1/2 in SOL.  A) No significant differences between 
treatments in 2hr Sol [CON vs EE (p=.121) and HS+EE (p=.183) and EE vs HS+EE 
(p=.942)].  B) No significant differences in 48hr Sol [CON vs EE (p=.334) and HS+EE 
(p=.928) and EE vs HS+EE (p=.325)]. 
 
Figure 4.8:  Phosphorylated ERK1/2 in VLR.  A) No significant differences between 
treatments in 2hr VLR [CON vs EE (p=.413) and HS+EE (p=.481) and EE vs HS+EE 
(p=.985)].  B) No significant differences in 48hr VLR [CON vs EE (p=.459) and HS+EE 
(p=.996) and EE vs HS+EE (p=.468)]. 
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Figure 4.9:  Phosphorylated ERK1/2 in VLW.  A) No significant differences between 
treatments in 2hr VLW [CON vs EE (p=.824) and HS+EE (p=.900) and EE vs HS+EE 
(p=.976)].  B) No significant differences in 48hr VLW [CON vs EE (p=.543) and 
HS+EE (p=.981) and EE vs HS+EE (p=.468)]. 
 
Figure 4.10:  Ratio of Phosphorylated to Total ERK1/2 in SOL.  A) No significant 
differences between treatments in 2hr Sol [CON vs EE (p=.084) and HS+EE (p=.179) 
and EE vs HS+EE (p=.831)].  B) No significant differences in 48hr Sol [CON vs EE 
(p=.376) and HS+EE (p=.917) and EE vs HS+EE (p=.402)]. 
 
Figure 4.11:  Ratio of Phosphorylated to Total ERK1/2 in VLR.  A) No significant 
differences between treatments in 2hr VLR [CON vs EE (p=.477) and HS+EE (p=.704) 
and EE vs HS+EE (p=.866)].  B) No significant differences in 48hr VLR [CON vs EE 
(p=.533) and HS+EE (p=.903) and EE vs HS+EE (p=.653)]. 
 
Figure 4.12:  Ratio of Phosphorylated to Total ERK1/2 in VLW.  A) No significant 
differences between treatments in 2hr VLW [CON vs EE (p=.956) and HS+EE (p=.832) 
and EE vs HS+EE (p=.917)].  B) No significant differences in 48hr VLW [CON vs EE 
(p=.373) and HS+EE (p=.886) and EE vs HS+EE (p=.451)]. 
 
Figure 4.13:  Total c-Src in SOL.  A) No significant differences between treatments in 
2hr Sol [CON vs EE (p=.919) and HS+EE (p=.884) and EE vs HS+EE (p=.484)].  B) No 
significant differences in 48hr Sol [CON vs EE (p=.714) and HS+EE (p=.881) and EE vs 
HS+EE (p=.924)]. 
 
Figure 4.14:  Total c-Src in VLR.  A) No significant differences between treatments in 
2hr VLR [CON vs EE (p=.477) and HS+EE (p=.125) and EE vs HS+EE (p=.090)].  B) 
No significant differences in 48hr VLR [CON vs EE (p=.405) and HS+EE (p=.116) and 
EE vs HS+EE (p=.571)]. 
 
Figure 4.15:  Total c-Src in VLW.  A) No significant differences between treatments in 
2hr VLW [CON vs EE (p=.950) and HS+EE (p=.964) and EE vs HS+EE (p=.998)].  B) 
No significant differences in 48hr VLW [CON vs EE (p=.103) and HS+EE (p=.312) and 
EE vs HS+EE (p=.665)]. 
 
Figure 4.16:  Phosphorylated c-Src 527 in SOL.  A) No significant differences between 
treatments in 2hr Sol [CON vs EE (p=.622) and HS+EE (p=.996) and EE vs HS+EE 
(p=.366)].  B) No significant differences in 48hr Sol [CON vs EE (p=.995) and HS+EE 
(p=.973) and EE vs HS+EE (p=.920)]. 
 
 49 
Figure 4.17:  Phosphorylated c-Src 527 in VLR.  A) No significant differences between 
treatments in 2hr VLR [CON vs EE (p=.157) and HS+EE (p=.540) and EE vs HS+EE 
(p=.481)]. B) No significant differences in 48hr VLR [CON vs EE (p=.755) and HS+EE 
(p=.940) and EE vs HS+EE (p=.884)]. 
 
Figure 4.18:  Phosphorylated c-Src 527 in VLW.  A) No significant differences 
between treatments in 2hr VLW [CON vs EE (p=.335) and HS+EE (p=.241) and EE vs 
HS+EE (p=.951)].  B) No significant differences in 48hr VLW [CON vs EE (p=.179) 
and HS+EE (p=.438) and EE vs HS+EE (p=.720)]. 
 
Figure 4.19:  Ratio of Phosphorylated to Total c-Src in SOL.  A) No significant 
differences between treatments in 2hr Sol [CON vs EE (p=.996) and HS+EE (p=1.000) 
and EE vs HS+EE (p=.997)].  B0 No significant differences in 48hr Sol [CON vs EE 
(p=.434) and HS+EE (p=.420) and EE vs HS+EE (p=.999)]. 
 
Figure 4.20:  Ratio of Phosphorylated to Total c-Src in VLR.  A) No significant 
differences between treatments in 2hr VLR [CON vs EE (p=.705) and HS+EE (p=.496) 
and EE vs HS+EE (p=.902)].  B) No significant differences in 48hr VLR [CON vs EE 
(p=.548) and HS+EE (p=.304) and EE vs HS+EE (p=.832)]. 
 
Figure 4.21:  Ratio of Phosphorylated to Total c-Src in VLW. A) No significant 
differences between treatments in 2hr VLW [CON vs EE (p=.575) and HS+EE (p=.679) 
and EE vs HS+EE (p=.975)].  B)  There were no significant differences in 48hr VLW 





























































































































































































There have been many experiments that have dealt with IN in various cells and 
conditions yet there is a lack of literature that deals with IN and SM, especially in healthy 
muscle cells.  This current study aimed to look at IN signaling in healthy rat SM after a a 
bout of eccentric exercise.  What our data demonstrates is a two hour eccentric exercise 
protocol, regardless of heat treatment, does not significantly alter IN levels or IN 
signaling in rat SOL, VLR and VLW muscles at 2hr and 48hr post exercise.  While there 
are not a lot of studies dealing with IN expression in SM without pathological conditions, 
there are a few similar studies that can adequately compare with the current study.  The 
outcomes of the current study contrast to a similar study carried out by Boppart, et al., 
(10).  They ran female mice downhill at a slightly slower speed (17m/min) and at a more 
severe grade (20°) compared to our study as well as exercising the mice for only 30 
minutes.  They saw a significant 70% increase in the expression of alpha7 subunit at 24 
hours post-exercise in the gastrocnemius and soleus complex and an elevated, although 
not significant, alpha7 level 1 week after the exercise protocol.   Since this study used 
mice, there may be the possibility that mice respond to eccentric contractions more 
readily than rats.  There is also the prospect that there could be a gender difference.  
Boppart and colleagues used females while this study used all males.  The duration of the 
exercise may have been a factor as well.  They report that they ran their mice for 30 min 
straight while the current study ran rats repeatedly for 5 minutes followed by a 2 minute 
break.  This break may be enough time to allow IN signaling to return to baseline 
although no study could be found that looked at IN and downstream signaling over time. 
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Boppart and colleagues also used this protocol several years later to look at mRNA 
expression of the alpha7 subunit (11).  This time they found a 5.4 fold increase 3 hours 
post exercise.  The levels returned to normal 24 hrs and 1 week post exercise.   This 
compliments the previously described study.  If the mRNA is increased drastically it may 
lead to the increase in protein expression seen 24 hrs and 1 week after exercise.  
Kääriäinen and colleagues (44) incited muscle damage by completely transecting SOL 
unilaterally and measuring recovery and alpha7beta1 expression over a span of 56 days.  
What they reported was an increase in the beta1variant beta1A, the variant most apparent 
in developing or recovering muscle, in stained regenerating muscle fibers at 2 days and 
an increase in appearance of the overall beta1 subunit by staining at the site of injury at 3 
days.  So while this may not fit perfectly in line with the current study is does show in 
increase in IN presence during recovery.  It is also possible that the transection is far 
more traumatic to the cell than a downhill exercise protocol and may induce a reaction 
that is larger in magnitude. 
 
We also know that IN are a major player in mechanotransduction. It has been shown that 
patients with Duchenne’s muscular dystrophy have an elevated level of alpha7beta1 
integrin using quantified staining and RT-PCR designed to detect alpha7 subunits (37).  
This upregulation of alpha7beta1 IN is obviously there to provide a backup mechanism 
for cellular protection and to anchor the cell during a muscular contraction.  A lack of the 
alpha7 subunit can be also be lethal in murines.  Welser and colleagues demonstrated that 
mice bred to lack only the alpha7 gene had a 54.3% death rate in utero, weighed 60% less 
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than wild type mice and had a 20% loss of strength compared to wild type mice (109).  
This again shows that IN are necessary for the transmission of force and cell survival.       
 
There have been no studies located that have looked at c-Src in SM in vivo, let alone 
exercise and SM.  To try and understand how exercise may activate c-Src in SM we can  
try to look at FAK.  The only study found concerning FAK and exercise used a resistance 
training protocol.  It was shown that doing 4 sets of 10 reps of isolateral leg extensions 
and leg press did not increase FAK activation (29).  We can then hypothesize that this 
exercise protocol is not sufficient to activate c-Src.  With the lack of information about c-
Src in SM, we must look to other cells such as cardiac tissue.  Kuppuswamy, et al., (54) 
used a pressure overloaded cat right ventricle and saw an increase in total c-Src at 4hr, a 
peak at 48hr and a return to baseline after 1 week.  This makes it somewhat surprising 
that we saw no difference in our c-Src totals, especially at the 48hr timepoint.  Again, this 
points to the possibility that the exercise protocol was not strenuous enough.  No study 
can be located that describes how quickly c-Src becomes activated through FAK.  But it 
should be noted that when placing angiotensin II (a c-Src activator) in cultured vascular 
smooth muscle cells and measuring the time points of c-Src activity, there was a 3 fold 
increase in c-Src activity within 3 minutes and then a gradual decline to 2 fold at 10 
minutes (41).  This again points to the fact that we may have missed the optimal time 
point.  It is also interesting that we did not see an increase in c-Src because it seems to be 
activated by stretch through a pathway other than FAK.  It was shown that stretching of 
C2C12 cells increased c-Src in the dystroglycan complex in an IN dependent manner and 
that inhibition of c-Src by the inhibitor PP2 stopped cell proliferation by 5 fold (115). 
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It was also surprising that there was no increase in ERK1/2 activation.  Martineau and 
Gardiner (65) have shown that EE has the largest impact in activating MAPK’s in rat 
skeletal muscle when compared to isometric and concentric By hooking rat SM into a 
muscle stimulator they found a five-fold increase in pERK1/2 compared to a control.  
They also found a three-fold increase in concentric contractions, making it even stranger 
that a 2hr eccentric exercise protocol did not result in an increase in ERK1/2 activation 
for the current study.  It has been shown that an acute bout of endurance exercise can 
activate ERK1/2 in human skeletal muscle.  Untrained but healthy men cycled at 70% 
VO2max for one hour and saw a dramatic increase in ERK1/2 activation immediately 
after exercise (7).  However, levels of pERK1/2 had returned to basal levels after three 
hours of recovery.  This shows that we may have missed the optimal time for seeing the 
elevated activation of ERK1/2.  We also may not have activated IN sufficiently enough to 
start the cascade.  In NRVM that had slightly dysfunctional beta1 subunits, there was 
decrease in activated FAK and ERK1/2 in stretched cells compared to control cells (55).  
What this demonstrates is that a functional beta1 signal is necessary for ERK1/2 
phosphorylation.  This study also found that when the cell had high levels of FRNK, a 
FAK inhibitor, then pERK1/2 levels go down, again showing that for full ERK1/2 
activation a valid IN related signal is necessary.  Takeishi, et al., (95) have shown a 6 fold 
increase of ERK1/2 activity at 10 min post cardiac overload in guinea pig hearts.  This 
peak activation then decreased 33% at 1day post.  Again, this is evidence that shows that 
we should have seen activation of ERK1/2.     
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It has already been stated that small heat shock proteins have been able to activate FAK 
(56, 108).  A limiting factor of this current study is that there was no analysis of FAK to 
determine if in the HS group there was an increase in FAK expression or activation 
comparatively.  It has recently been shown that HS may activate alpha3beta1 IN.  In 
breast carcinoma cell lines, researchers demonstrated that Hsp60 immunoprecipitates 
with alpha3beta1 IN (5).  They also showed that in cells with recombinant Hsp60, the cell 
with the alpha3 subunit demonstrated increased motility compared to an alpha2 subunit.  
This shows that Hsp60 can activate IN with a beta1 subunit but is dependent on the alpha 
subunit.  It has also been shown that Hsp 60 can create bridges with fibronectin, 
fibronection binding protein, and beta1 subunits in endothelial cells (23) ultimately 
causing the activation of the IN in epithelial cells.  Since we only looked at total beta1 
subunit, it is quite possible that there may be an increase in activated IN in the HS group 
because of the relationship with Hsp60.  Hsp may play a role downstream of IN.  In 
cervical cancer cells, the inhibition of Hsp90 attenuates activation of FAK and hinders 
tumor growth (92) giving Hsp90 a role of, perhaps, protecting FAK or IN signaling.  
Again, we would need to look at FAK activation to see how this interaction with Hsp90 
could potentially affect our samples.  Even further down the pathway, elevating heat in 
NIH3T3 cells to 43°C for 10 minutes increased activation of c-Src by a little over 2 fold 
after 5 minutes and maintained elevated levels for 15 minutes (60).  The study also 
showed an increase in ERK1/2 activity.  Lastly, ERK1/2 activation was increased 60 fold 
in heat shocked interleukin 3 cells (74) at 60 min and 120 min.  So, again, it is very 




An apparent limitation of this study was the lack of focus on FAK.  Considering that Hsp 
and IN can activate it, to get a clarified view of the complete IN signaling pathway, 
looking at FAK is a must.  Also, trying to determine activation of IN was a limiting factor 
of this study.  It would provide a glimpse into determining if our protocol is sufficient 
enough to cause IN activation and, in turn, determine what exercise and load may be 
necessary to activate these proteins.   
 
Sample size was also a limiting factor.  Because of our small sample sizes, we had very 
large variabilities in our densitometry values, possibley making it more difficult to find 
an accurate and possibly significant outcome.   
 
Our time points may have been a limiting factor.  It has been seen that ERK1/2 has been 
activated at the time points we covered but c-Src seems to become active very quickly 
and may not have had enough activity at the 2hr and 48hr post-exercise timepoints.   
 
It may also be possible that our exercise protocol may not have been sufficient to activate 
these proteins.  The study that found increases in alpha7 expression (10) used a more 
aggressive slope for a continuous amount of time while our study was a two hour 
protocol.   
Future Research 
There is still plenty of information that needs to be resolved with IN signaling in SM.  
First, it needs to be known what the appropriate magnitude of muscular contraction is 
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needed to reliably and repeatedly activate IN.  It also needs to be determined what is the 
optimal timing of all of these IN related proteins.  If we can accurately predict when FAK 
is activated we may better understand its role in the pathways that it controls and how 
specific these pathways are in regards to contraction and HS.  It also needs to be 
determined if HS plays a major role in SM through FAK.  Studies could possibly look 
into using pharmacological inhibitors to determine which pathways HS and FAK may go 
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SOL: (CON=3: 15527485±4421965; EE; n=8: 14609996±7711416; HS+EE: n=8; 
13531410±6201014)  
VLR: (CON=3; 10563617±4836214; EE=8; 11661395±6276239; HS+EE=8; 
12671899±6270266)  
VLW: (CON =3; 3679673±729936; EE=8; 4257895±1350019; HS+EE=8; 
4622543±2231892)  
 
Significance Levels for 2hr 
 
CON compared to EE (SOL:  p=.980; VLR:  p=.962; VLW: p=.877) and HS+EE (SOL:  
p=.966; VLR:  p=.868; VLW:  p=.709) and EE compared to HS+EE (SOL:  p=.997; 




SOL: (CON=3; 20353252±10467104; EE:n=8; 14688935±14096905; HS+EE: n=8; 
16881546±12097800) 
VLR: (CON=3; 1337774±653482; EE=8; 4797242±4596025; HS+EE=8; 
4016059±3632115)  
VLW: (CON=3; 22594159±3965464; EE=8; 15440392±6523425; HS+EE=8; 
15275500±7872437) in  
 
Significance levels for 48hr 
 
CON compared to EE (SOL:  p=.947; VLR:  p=.407;  VLW:  p=.304) and HS+EE (SOL:  
p=.998; VLR:  p=.576; VLW:  p=.289) and EE compared to HS+EE (SOL:  p=.938; 
VLR:  p=.915; VLW:  p=.999). 
 




SOL: (CON=3; 49370528±11201938; EE=8; 47391828±;8230230; HS+EE=8; 
49642664±7401158) 
VLR: (CON=3; 40735017±6916230; EE=8; 39115421±11999886; HS+EE=8; 
36429977±12768147)  
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VLW” (CON=3; 7408697±875360; EE=8; 11944792±4834850; HS+EE=8; 
10837911±3136231)  
 
Significance levels for 2hr 
 
CON compared to EE (SOL:  p=.935; VLR:  p=.978; VLW: p=.217) and HS+EE (SOL:  
p=.999; VLR:  p=.855; VLW:  p=.403)  as well as EE compared to HS+EE (SOL:  




SOL (CON=3; 54718601±5998325; EE=8; 76645228±23895526; HS+EE=8; 
73554507± 23794117) 
VLR (CON=3; 59610097±1531669; EE=8; 56496705±16423238; HS+EE=8; 
49270037±4713228)  
VLW (CON=3; 15130711±2601159; EE=8; 13463864±2716538; HS+EE=8; 
13673163±2755272) i 
 
Significance levels for 48hr 
 
CON compared to EE (SOL:  p=.342; VLR:  p=.913; VLW: p=.645) and HS+EE (SOL:  
p=.447; VLR:  p=.389; VLW: p=.713)as well as EE compared to HS+EE (SOL:  p=.959; 
VLR:  p=.427; VLW: p=..987).    
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Significance levels for 2hr 
 
CON compared to EE (SOL:  p=.121; VLR:  p=.413; VLW: p=.824) and HS+EE (SOL:  
p=.183; VLR:  p=.481; VLW: p=.900) as well as EE compared to HS+EE (SOL:  




SOL (CON=3; 913114±186539; EE=8; 5063657±6193931; HS+EE=8; 
1957082±1322926) 
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Significance levels for 48hr 
 
CON compared to EE (SOL:  p=.334; VLR:  p=.459; VLW: p=.543) and HS+EE (SOL:  
p=.928; VLR:  p=.996; VLW: p=.981) as well as EE compared to HS+EE (SOL:  
p=.325; VLR:  p=.298; VLW: p=.468).    
 




SOL (CON=3; 0.0258±0.0092; EE=8; 0.0930±0.0441; HS+EE=8; 0.0804±0.0477) 
VLR (CON=3; 0.6267±0.4831; EE=8; 0.4239±0.1088; HS+EE=8; 0.4887±0.2586) 
VLW (CON=3; 0.7349±0.2916; EE=8; 0.6673 ±0.4057; HS+EE=8; 0.5981±0.2960)  
 
Significance levels for 2hr 
 
CON compared to EE (SOL:  p=.084; VLR:  p=.477; VLW: p=.956) and HS+EE (SOL:  
p=.179; VLR:  p=.704; VLW: p=.832) as well as EE compared to HS+EE (SOL:  




SOL (CON=3; 0.0169±0.0201; EE=8; 0.0612±0.0672; HS+EE=8; 0.0297±0.0252) 
VLR (CON=3; ±; EE=8; ±; HS+EE=8; 0.3249±0.2057)  
VLW (CON=3; 0.2704±0.0401; EE=8; 0.4303±0.1547; HS+EE=8; 0.3249 ±0.2056)  
 
Significance levels for 48hr 
 
CON compared to EE (SOL:  p=.376; VLR:  p=.533; VLW: p=.373) and HS+EE (SOL:  
p=.917; VLR:  p=.903; VLW: p=.886) as well as EE compared to HS+EE (SOL:  
p=.402; VLR:  p=.653; VLW: p=.451). 
 
Raw data for total c-Src 
 
SOL (CON=3; 20377220 ±;3977999; EE=8; 17128394±3696279; HS+EE=8; 
24300200±17951048) 
VLR (CON=3; 2992104±513944; EE=8; 2834206±527760; HS+EE=8; 
2188772±622517)  
VLW (CON=3; 5957222±2143974; EE=8; 6594353±4013056; HS+EE=8; 
6497261±2068889)  
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Significance levels for 2hr 
 
CON compared to EE (SOL:  p=.919; VLR:  p=.912; VLW: p=.950) and HS+EE (SOL:  
p=.884; VLR:  p=.125; VLW: p=.964) as well as EE compared to HS+EE (SOL:  




SOL (CON=3; 20531935±6406617; EE=7; 23001243±;10110414; HS+EE=8; 
20981690±6136075) 
VLR (CON=3; 9900282±1459552; EE=6; 7408331±3861995; HS+EE=6; 
5831627±997033)  
VLW (CON=3; 2397282±82306; EE=8; 1705359±296730; HS+EE=8; 
2011459±554459)  
 
Significance levels for 48hr 
 
CON compared to EE (SOL:  p=.714; VLR:  p=.405; VLW: p=.103) and HS+EE (SOL:  
p=.881; VLR:  p=.116; VLW: p=.312) as well as EE compared to HS+EE (SOL:  
p=.924; VLR:  p=.571; VLW: p=.665). 
 




SOL (CON=3; 10299912 ±2003146; EE=8; 8807499±2855305; HS+EE=8; 
10439998±1785886) 
VLR (CON=3; 545397±173578; EE=8; 1466511±738640; HS+EE=8; 
1054837±746511)  
VLW (CON=3; 1580863±334081; EE=8; 4673119±2814126; HS+EE=8; 
5147270±3790516)  
 
Significance levels for 2hr 
 
CON compared to EE (SOL:  p=.622; VLR:  p=.157; VLW: p=.335) and HS+EE (SOL:  
p=.996; VLR:  p=.540; VLW: p=.241) as well as EE compared to HS+EE (SOL:  




SOL (CON=3; 0.0169±0.0201; EE=8; 0.0612±0.0672; HS+EE=8; 0.0297±0.0252) 
VLR (CON=3; 392815±193715; EE=8; 634227±526302; HS+EE=8; 517386±275354) 




Significance levels for 48hr 
 
CON compared to EE (SOL:  p=.995; VLR:  p=.755; VLW: p=.179) and HS+EE (SOL:  
p=.973; VLR:  p=.940; VLW: p=.438) as well as EE compared to HS+EE (SOL:  
p=.920; VLR:  p=.884; VLW: p=.720). 
 




 SOL (CON=3; 0.5234 ±0.1688; EE=8; 0.5083±0.1008; HS+EE=8; 0.5341±0.1757), 
VLR (CON=3; 0.0389±0.0154; EE=8; 0.0704±0.0310; HS+EE=8; 0.0844±0.0556)  
VLW (CON=3; 0.2800±0.0708; EE=8; 1.1161±0.9540; HS+EE=8; 1.0004±0.8577)  
 
Significance levels for 2hr 
 
CON compared to EE (SOL:  p=.996; VLR:  p=.705; VLW: p=.575) and HS+EE (SOL:  
p=.1.00; VLR:  p=.496; VLW: p=.679) as well as EE compared to HS+EE (SOL:  




SOL (CON=3; 0.3066±0.1090; EE=7; 0.2219±0.0647; HS+EE=8; 0.2130±0.0812) 
VLR (CON=3; 0.0389±0.0154; EE=6; 0.0704±0.0310; HS+EE=8; 0.0844±0.0556) 
VLW (CON=3; 1.7919±0.0652; EE=8; 1.9343±0.4772; HS +EE=8; 1.8891±0.3179)  
 
Significance levels for 48hr 
 
 CON compared to EE (SOL:  p=.434; VLR:  p=.548; VLW: p=.996) and HS+EE (SOL:  
p=.420; VLR:  p=.304; VLW: p=.969) as well as EE compared to HS+EE (SOL:  
p=.999; VLR:  p=.832; VLW: p=.918).  
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